pISSN 2234-3806eISSN 2234-3814
Table. 4.
Comparison of published studies on cfDNA in HCC patients using targeted sequencing
| Reference | Stage of HCC | Sample | Genes | Median coverage (range) | Claimed analytical sensitivity | Most common altered gene | Detection of ≥1 somatic variants in cfDNA (%) | Median variant allele frequency (%) |
|---|---|---|---|---|---|---|---|---|
| Howell, |
early (39%) and advanced (61%) HCC | N= 51 | 8 | 486x (IQR: 234x–797x) | NA | 35 | 11.9 (IQR: 5–42.3) | |
| (8 with paired tumor biopsy) | ||||||||
| Kaseb, |
advanced HCC | N= 206 | 54–70 | NA | 0.1% LoD | NA (detection of ≥ 1 alterations in cfDNA: 87.8) | 0.49 (range, 0.06–55.03) | |
| Ng, |
early (67%) and advanced (33%) HCC | N= 30 | 46 | 1,239x (703x–3,244x) | 0.1% LoD | 63 | 13.7 (range, 0.06–44.9) | |
| (with paired tumor biopsy) | ||||||||
| Present study | advanced HCC | N= 20 | 3 | 63,482x (44,765x–81,672x) | 0.1% LoD | 65 | 0.13 (range, 0.06–6.99) | |
Abbreviations: cfDNA, cell-free DNA; HCC, hepatocellular carcinoma; NA, not available; LoD, limit of detection; IQR, interquartile range.
Ann Lab Med 2021;41:198~206 https://doi.org/10.3343/alm.2021.41.2.198
© Ann Lab Med